Trials / Completed
CompletedNCT04963725
A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice
Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice, Measured Using Patient-Reported Outcomes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 137 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the initial response to ustekinumab induction treatment for ulcerative colitis (UC) in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ustekinumab | No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected. |
Timeline
- Start date
- 2021-07-18
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2021-07-15
- Last updated
- 2025-04-28
Locations
23 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04963725. Inclusion in this directory is not an endorsement.